Amneal Pharmaceuticals, Inc. 4

Director Yanai Shlomo reported routine RSU-related acquisitions and settlements into Amneal Pharmaceuticals, Inc. (AMRX) Class A Common Stock, increasing his direct holdings to 320,804 shares.

On this Form 4, reporting person Yanai Shlomo, a director of Amneal Pharmaceuticals, Inc., reported routine equity compensation activity involving restricted stock units ("RSUs") and the corresponding issuance of Class A Common Stock. On May 7, 2026, 34,819 RSUs previously granted (notably described as having been granted on May 6, 2025 and vesting on May 7, 2026) were settled in shares, reflected as a Section 16 code "M" transaction: 34,819 RSUs were converted and 34,819 shares of Class A Common Stock were acquired, resulting in a reported direct ownership position of 320,804 shares of Class A Common Stock. Separately, an additional award entry dated May 6, 2026 shows 19,824 RSUs granted (again with $0 price, typical for equity awards) and a corresponding entry of 19,824 shares of Class A Common Stock, consistent with the Form 4’s notation that each RSU represents a contingent right to receive one share; these appear to be routine director compensation grants/vestings rather than open‑market purchases or discretionary sales. No transaction prices or market values were provided in the filing, so the dollar value of the transactions and the post‑transaction ownership value must be inferred as zero in the absence of pricing data.

Filing Facts

CIK

1723128

Ticker

AMRX

Form

4

Source Type

sec

Accession

0001628280-26-032904

Alert Tier

5